Adalimumab-Fkjp(Cf) Pen(Adalimumab-Fkjp)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$182K
Medicare cost, 2024
$182K
Medicare cost, 2024
Medicare drug plans spent $182,096 on Adalimumab-Fkjp(Cf) Pen (adalimumab-fkjp) in 2024, for 169 prescriptions and refills filled by 43 patients. Spending rose 308% from 2023 to 2024. California accounts for the most spending ($25,453, 14% of the total).
Medicare cost, 2024
$182K
+307.8% from 2023
Prescriptions
169
$1,077.49 per claim
Patients
43
43 prescribers
Total spending, 2024
$182K
$4,234.80 per patient
Questions and answers
How much does Medicare spend on Adalimumab-Fkjp(Cf) Pen?
Medicare prescription drug plans paid $182K for Adalimumab-Fkjp(Cf) Pen in 2024, for 169 prescriptions and refills to 43 patients (up 307.8% from 2023). The average cost per claim was $1,077.49.
Which state spends the most on Adalimumab-Fkjp(Cf) Pen?
California had the highest Medicare cost for Adalimumab-Fkjp(Cf) Pen in 2024: $25K for 24 claims, followed by Oregon ($22K).
Who prescribes Adalimumab-Fkjp(Cf) Pen the most?
Christopher S Cutler, gastroenterology in Sandy, UT, had the highest Medicare cost for Adalimumab-Fkjp(Cf) Pen in 2024: 13 claims costing $14K.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
Medicare spending on Adalimumab-Fkjp(Cf) Pen was $182K in 2024, the highest year shown.
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Top prescribers of Adalimumab-Fkjp(Cf) Pen, 2024
By Medicare drug cost
| Prescriber | Type | Claims | Patients | Cost |
|---|---|---|---|---|
| Christopher S Cutler Sandy, UT | Gastroenterology | 13 | Under 11 | $14K |
| James R Rummel Jr. Hermitage, PA | Family Practice | 11 | Under 11 | $11K |
| Fernando J Pardo-Ruiz Deming, NM | Internal Medicine | 12 | Under 11 | $11K |
| Anish A Sheth Princeton, NJ | Gastroenterology | 11 | Under 11 | $11K |
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2023 | 11 | 31 | 11 | $45K |
| 2024 | 43 | 169 | 43 | $182K |
Makers, 2024
Spending by manufacturer as listed in the spending data
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 47,987 side-effect reports named adalimumab-fkjp, the active ingredient of Adalimumab-Fkjp(Cf) Pen (reports from 2004 on). 45,657 of them (95.1%) were serious, 7,068 named a death and 17,064 named a hospital stay. The reactions named most often were drug ineffective, off label use and rheumatoid arthritis. 35,192 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
47,987
8,520 in 2025 (-2.8% from 2024)
Serious
95.1%
45,657 reports
Deaths named
7,068
14.7% of reports
Hospital stays
17,064
35.6% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Adalimumab-Fkjp(Cf) Pen?
47,987 reports from 2004 through September 2026 named adalimumab-fkjp, the active ingredient of Adalimumab-Fkjp(Cf) Pen. 45,657 of them (95.1%) were serious, 7,068 named a death and 17,064 named a hospital stay.
What are the most reported side effects of Adalimumab-Fkjp(Cf) Pen?
10,847 reports named drug ineffective, the reaction named most often, followed by off label use (8,865) and rheumatoid arthritis (5,991). In the last 5 years the reaction named most often was off label use (7,209 reports). A report can name several reactions.
How many side-effect reports named Adalimumab-Fkjp(Cf) Pen in 2025?
8,520 reports were received in 2025 (-2.8% from 2024). 2026 so far: 5,753 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Adalimumab-Fkjp(Cf) Pen caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Adalimumab-Fkjp(Cf) Pen caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with adalimumab-fkjp: Hulio(Cf) Pen, Hulio(Cf), Adalimumab-Fkjp(Cf)
- Makers on the stock market:
VTRS·VTRS drug pipeline - Drug approvals · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (adalimumab-fkjp) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.